健康元：健康元药业集团股份有限公司2025年第三季度报告（英文）

Stock Code: 600380 Joincare Pharmaceutical Group Industry Co., Ltd.2025ThirdQuarterly Report The Board of Directors and all Directors of the Company hereby warrant that there are no falserepresentations, misleading statements or material omissions contained in this announcement andaccept legal responsibility for the truthfulness, accuracy and completeness of the contents hereof. IMPORTANT NOTICE: ⚫The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior managementof the Company hereby warrant the truthfulness, accuracy and completeness of the contents of thisquarterly report, and that there are no false representations, misleading statements or materialomissions contained herein, and severally and jointly accept legal responsibility.⚫The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant thetruthfulness, accuracy and completeness of the financial information contained in this quarterly report.⚫Whether thefirstquarterly financial statements have been audited.□Yes√No I. MAJOR FINANCIAL DATA (I) Major Accounting Data and Financial Indicators Notes: The“Reporting Period”represents the 3-month period from the beginning to the end of thisquarter, the sameasbelow. For the items not listed in the“Explanatory Announcement No.1 for Public Company InformationDisclosures-Extraordinary Gains or Losses”that the company identifies as non-recurring gains and losses,especially those with significant amounts, as well as the extraordinary gain or loss items as illustrated inthe“Explanatory Announcement No.1 for Public Company Information Disclosures-Extraordinary Gainsor Losses”which has been defined as its recurring gain or loss items, the reasons for such classificationshould be explained. □Applicable√N/A (III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof□Applicable√N/A (IV) Material Changes in Other Items in Financial Statements and Financial Indicators and ReasonsThereof II. SHAREHOLDERS (I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored Voting Rights and Shareholdings of Top 10 Shareholders Unit: shares Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholderswithout selling restriction in securities lending transactions of refinancing business□Applicable√N/A Changes in the top 10 shareholders and the top 10 shareholders without selling restriction due tosecurities lending/returning transactions of refinancing business compared to the previous period□Applicable√N/A III. OTHER REMINDERS Other important information regarding the Company’s operations during the Reporting Period to whichinvestors should be reminded to pay attention. √Applicable □N/A Use of Proceeds Pursuant to theSelf-Regulatory Guidelines for Listed Companies on the Shanghai Stock ExchangeNo. 1–Standardized Operation, upon the completion of all projects funded by the proceeds, anyremaining proceeds (including interest income) shall be subject to review and approval by the board ofdirectors of the listed company, and the sponsor or independent financial adviser shallissue a clear opinionthereon. The company shall make a timely announcement after the board’s deliberation. If the remainingproceeds (including interest income) account for more than 10% of the net proceeds raised, such mattershall also be submitted tothe general meeting of shareholders for approval. If the remaining proceeds(including interest income) are less than RMB 5 million or less than 5% of the net proceeds raised, theabove procedures may be exempted, and the use of such remaining proceeds shall be disclosed in the mostrecent periodic report. As of30 September 2025,the proceeds raised from the Company’s rights issue have been fullyutilized, and all projects funded by the rights issue have been completed. The Company will cancel thedesignated proceeds account, and the Tripartite Supervision Agreement on the Management of Proceedsentered into among the Company, the sponsor institution, and the commercial bankwillaccordinglybeterminated. IV. QUARTERLY FINANCIAL STATEMENTS (I) Audit Opinion□Applicable√N/A(II) Financial Statements Consolidated Balance Sheet Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Person-in-charge of theCompany: Zhu BaoguoPerson-in-charge of theCompany's accounting work:Qiu QingfengPerson-in-charge of theaccounting department:Guo Chenlu Consolidated Income Statement From January toSeptember, 2025 Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Person-in-charge of theCompany: Zhu BaoguoPerson-in-charge of theCompany's accounting work:Qiu QingfengPerson-in-charge of theaccounting department:Guo Chenlu Consolidated Cash Flow Statement Person-in-charge of theCompany: Zhu BaoguoPerson-in-charge of theCompany's accounting work:Qiu Qi